uniQure Q2 2020 Earnings Report
Key Takeaways
uniQure reported its financial results for the second quarter of 2020. They entered into an exclusive global license agreement with CSL Behring for their gene therapy candidate for hemophilia B and completed the first patient dosing in a Phase I/II clinical trial of AMT-130 in Huntington’s Disease.
Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B.
Completed First Patient Dosing in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease.
Cash and cash equivalents totaled $314.3 million as of June 30, 2020.
uniQure is eligible following regulatory approval to receive more than $2 billion of economics from CSL Behring, including upfront cash, milestone, and royalty payments
uniQure
uniQure
Forward Guidance
This press release contains forward-looking statements. uniQure’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons.